Evidence map›Paper›PMID 32271686›Full record

ArticleCirculation research2020

A T-Cell Small RNA With miRacle Effects on Aortic Stiffening.

David M Patrick, David G Harrison

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

David M PatrickFrom the Divisions of Cardiology (D.M.P.), Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
David G HarrisonFrom the Divisions of Cardiology (D.M.P.), Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.

Funding

The Role of Inflammation in Cardiovascular DiseaseP01HL129941 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNSTEIN, KENNETH E · 2016 to 2020
$12.4M
Mechanisms of Immune Activation in HypertensionR35HL140016 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HARRISON, DAVID G · 2018 to 2024
$5.3M
Vanderbilt Hypertension and Blood Pressure Regulation ProgramT32HL144446 · NHLBI · VANDERBILT UNIVERSITY · PI HARRISON, DAVID G · 2019 to 2023
$1.7M
A Role of Isolevuglandin Adducts in Essential Hypertension and Systemic Lupus ErythematosusK08HL153789 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PATRICK, DAVID · 2020 to 2021
$317k
Isolevuglandin peptide modification and proteasomal processing is responsible for autoimmune mediated hypertensionF32HL144050 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PATRICK, DAVID · 2019 to 2019
$70k
Medical Research Council MR/S005412/1NHLBI NIH HHS F32 HL144050NHLBI NIH HHS K08 HL153789NHLBI NIH HHS P01 HL129941NHLBI NIH HHS R35 HL140016NHLBI NIH HHS T32 HL144446
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HypertensionMicroRNAsAortaFibrosisHumansT-LymphocytesMicroRNAsMIRN214 microRNA, humanallergy and immunologyEditorialshumanshypertensionvascular stiffness

Identifiers

PMID32271686
PMCPMC7164651

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.